Metsera's CEO Whit Bernard on the obesity space, including GLP-1s, amylin analogs, and how the company is also developing both as oral peptides

blonca9
Apr 23
1 min read

He describes how Metsera, which had its IPO two months ago, is aiming to develop a differentiated GLP-1 vs currently marketed products by having a lower dose and longer half-life. We discuss all the hot button issues in the obesity space today.

Recent Posts

See All

CREATE Medicines' platform allows it to program CARs into multiple immune cell types inside the body, and is redosable. While this includes CAR-T, they believe that "in vivo is more than T-cells."

The leaders of London based LabGenius Therapeutics discuss a recent ESMO IO poster for their Nectin-4 x CD3 T-cell engager, and a new expanded collaboration with Sanofi on antibody optimization

Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today

Metsera's CEO Whit Bernard on the obesity space, including GLP-1s, amylin analogs, and how the company is also developing both as oral peptides

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight